Lyell Wealth Management LP Raises Stock Holdings in Stryker Corporation $SYK

Lyell Wealth Management LP boosted its holdings in shares of Stryker Corporation (NYSE:SYK) by 5.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 40,610 shares of the medical technology company’s stock after purchasing an additional 2,077 shares during the quarter. Lyell Wealth Management LP’s holdings in Stryker were worth $14,273,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Godfrey Financial Associates Inc. purchased a new position in Stryker during the fourth quarter worth approximately $26,000. United Financial Planning Group LLC purchased a new position in Stryker during the third quarter worth approximately $27,000. CGC Financial Services LLC purchased a new position in Stryker during the fourth quarter worth approximately $29,000. Strive Asset Management LLC purchased a new position in Stryker during the third quarter worth approximately $30,000. Finally, ANTIPODES PARTNERS Ltd purchased a new position in Stryker during the third quarter worth approximately $34,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of Stryker stock opened at $305.82 on Friday. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The company has a market cap of $117.24 billion, a price-to-earnings ratio of 35.40, a PEG ratio of 1.95 and a beta of 0.78. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The business’s 50 day moving average price is $316.75 and its 200 day moving average price is $344.20.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter in the previous year, the business posted $2.84 EPS. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts predict that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Wells Fargo & Company lowered their price target on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Truist Financial restated a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Citigroup decreased their target price on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Sanford C. Bernstein set a $410.00 target price on Stryker in a research report on Friday, May 1st. Finally, William Blair restated an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $395.33.

Insider Buying and Selling

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by corporate insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.